Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Gains from Investment Securities (2017 - 2025)

Arcus Biosciences has reported Gains from Investment Securities over the past 9 years, most recently at -$5.0 million for Q4 2025.

  • Quarterly results put Gains from Investment Securities at -$5.0 million for Q4 2025, up 79.17% from a year ago — trailing twelve months through Dec 2025 was -$5.0 million (up 77.27% YoY), and the annual figure for FY2025 was -$5.0 million, up 77.27%.
  • Gains from Investment Securities for Q4 2025 was -$5.0 million at Arcus Biosciences, up from -$24.0 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for RCUS hit a ceiling of $14.0 million in Q4 2023 and a floor of -$24.0 million in Q4 2024.
  • Median Gains from Investment Securities over the past 5 years was -$279000.0 (2021), compared with a mean of -$411764.7.
  • Peak annual rise in Gains from Investment Securities hit 11211.11% in 2022, while the deepest fall reached 2350.98% in 2022.
  • Arcus Biosciences' Gains from Investment Securities stood at $3.8 million in 2021, then crashed by 126.67% to -$1.0 million in 2022, then soared by 1500.0% to $14.0 million in 2023, then plummeted by 271.43% to -$24.0 million in 2024, then surged by 79.17% to -$5.0 million in 2025.
  • The last three reported values for Gains from Investment Securities were -$5.0 million (Q4 2025), -$24.0 million (Q4 2024), and $1.0 million (Q3 2024) per Business Quant data.